Bemnifosbuvir
Highest phase reached
Phase 3
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 3
- Drug type
- Small molecule
- Drug name
- Bemnifosbuvir
- Molecular weight
- 581.54
- Structure (SMILES)
- CNc1nc(N)nc2c1ncn2[C@@H]1O[C@H](COP(=O)(N[C@@H](C)C(=O)OC(C)C)Oc2ccccc2)[C@@H](O)[C@@]1(C)F
- arbemnifosbuvir
- Arbemnifosbuvir
- at 511
- at 527 free base
- AT-511
- AT-527 free base
- bemnifosbuvir
- Bemnifosbuvir
- bemnifosbuvir [INN]
- BEMNIFOSBUVIR [USAN]
- Bemnifosbuvir [WHO-DD]
- bemnifosbuvir inn
- bemnifosbuvir usan
- bemnifosbuvir who dd
- CAS registry numbers
- 1998705-64-8
- ChEMBL ID
- CHEMBL5095404
- InChIKey
- OISLSHLAXHALQZ-HEOQURLSSA-N
- FDA ingredient codes (UNII)
- 7UM3SQL968
- 122527275
- 122527455
- First in class
- No
- Orphan designation
- No
- Pharmacology name
- bemnifosbuvir
- Type
- Synthetic organic
- Drug name stem
- -fos-; -vir
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000694
- Subject identifier
- D045169
- Condition
- Liver Diseases
- Highest recorded phase
- 1
- Condition identifier
- EFO:0001421
- Subject identifier
- D008107
- Condition
- COVID-19
- Highest recorded phase
- 1
- Condition identifier
- MONDO:0100096
- Subject identifier
- D000086382
- Condition
- Severe Acute Respiratory Syndrome
- Highest recorded phase
- 3
- Condition identifier
- MONDO:0100096
- Subject identifier
- D045169
- Condition identifier
- EFO_0001421
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005231
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0100096
- Highest recorded phase
- 3
- NCT05629962
- NCT05724693
- Hydrogen bond acceptors
- 13
- Hydrogen bond donors
- 4
- Polar surface area
- 184.97
- Calculated partition coefficient (ALogP)
- 2.57
- Calculated partition coefficient (XLogP)
- 1.7
- Prodrug
- Yes
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 2
- Rotatable bonds
- 11
- Heavy atoms
- 40
- Molecular formula
- C24H33FN7O7P
- Monoisotopic mass
- 581.21631158
- Natural product
- No
- Recorded assays
- 4
- Active assays
- 4
Active assay types
- Confirmatory
Related records
Trials (11)
- A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
- C-BEYOND: Efficacy and Safety of BEM/RZR vs. SOF/VEL in Subjects With Chronic HCV
- C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV
- Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)
- Drug-drug Interaction Study of Biktarvy and Bemnifosbuvir/Ruzasvir
- Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir
- Study of Bemnifosbuvir in Subjects With Normal and Impaired Hepatic Function
- Study of Bemnifosbuvir on Cardiac Repolarization in Healthy Subjects
- Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepatic Function
- SUNRISE-3: Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19
- The Study of Bemnifosbuvir in Healthy Japanese Subjects
In development for (3)
- COVID-19 Phase 3
- Liver disorder Phase 1
- Severe acute respiratory syndrome Phase 3